Standard market action is of little interest to stocks operating in the biotech space that happen to post good news. Say, the market is taking a beating – a regular occurrence these days – and a biotech announces results that show a clinical trial has gone very well, indicating its drug could help patients suffering from a hard-to-treat condition, then what do you get? A stock that completely sidesteps the overall pullback – and some.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Case in point: Madrigal Pharmaceuticals (MDGL) shares blasted 268% higher in Monday’s session after resmetirom, the company’s treatment for nonalcoholic steatohepatitis (NASH), a potentially lethal liver condition, excelled in a late-stage study.
More specifically, the drug met the primary endpoints in the Phase 3 MAESTRO-NASH trial. 30% of patients who were given a higher dose of the drug displayed resolution of NASH, while 26% of patients who were given the lower dose showed resolution. Liver fibrosis improvement was seen by 26% of patients at the higher dose group, and 24% from the lower dose cohort.
With no standard treatments currently available for NASH patients, JMP analyst Jonathan Wolleben says the results amount to the “grand slam scenario.” “Resmetirom looks approvable based on the Phase 3 MAESTRO-NASH data with a clinical profile supporting a blockbuster opportunity,” the analyst went on to add.
Even taking into account the fact the shares more than tripled in a single session, Wolleben recommends investors keep on loading up because: “1) the current valuation underappreciates the blockbuster opportunity afforded by the strength of the MAESTRO-NASH data (we model U.S. sales of ~$5B at peak penetration); and 2) MDGL now becomes a top M&A target and there is no shortage of large players with NASH exposure (Novo Nordisk, Novartis, Pfizer, Lilly, Merck, AstraZeneca, Gilead to name a few) that could drive up a takeout premium.”
Nikic doesn’t just lay out an upbeat path for the company, he backs it with an Outperform (i.e. Buy) rating and $312 price target. Going by this target, there’s room for an additional 33% gain from current levels. (To watch Wolleben’s track record, click here)
Overall, MDGL shares have a Strong Buy rating from the analyst consensus, showing that Wall Street agrees with Wolleben’s assessment. The rating is based on 9 Buys and 2 Holds set in the past 3 months. Shares are selling for $250, and the average price target, at $281.5, implies ~13% upside potential. (See MDGL stock forecast on TipRanks)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
